PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
1 EVALUATION OF THE BIOAVAILABILITY OF DICLOFENAC  DERMAL PRODUCTS  
 
Short title:  PK and TS of diclofenac  dermal  products  
UMB IRB #:  HP -00067047  
 
Principal Investigator:   
[INVESTIGATOR_39432] L. Stinchcomb (contact), PhD , RPh  
 
Medically Accountable Investigator(s):  
Jeffrey Fink, MD, MS  
Lee-Ann Wagner, MD  
 
Sponsor:  
Food and Drug Administration  
Office of Generic Drugs  
 
Grant Number: 1U01FD004947   
[STUDY_ID_REMOVED]  
Version 11.0 
07 June 2019  
 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
2 STATEMENT OF COMPLIANCE  
This trial will be conducted in compliance with the protocol, International Conference on 
Harmonization  Good Clinical Practice E6 (ICH -GCP) and the applicable Food and Drug 
Administration and other Department of Health and Human Services regulatory require ments.  
All key personnel (all individuals responsible for the design and conduct of this study) have 
completed Human Subjects Protection Training.  
  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
3 PROTOCOL SUMMARY  
Title:   Evaluation of the bioavailability of diclofenac  dermal products  
Population:  Healthy  adults age 18 - 45 years  
Number of Sites:  Single site: University of Maryland School of Medicine  
Study Duration:  Approximately up to [ADDRESS_655058] Participation 
Duration:  Approximately [ADDRESS_655059] : Diclofenac epolamine  (Flector¬Æ) patch  1.3%, Teikoku Seiyaku 
Co., Ltd ; Diclofenac sodium (Pennsaid¬Æ) topi[INVESTIGATOR_166461]  2%, 
Horizon Pharma [LOCATION_003] Inc.  
 
Objective : 
  
The present study aims to generate human tape strippi[INVESTIGATOR_007]  (TS) 
and pharmacokinetic (PK) data in healthy subjects for the 
purpose of establishing a reference for in vitro-in vivo  correlation  
(IVIVC)  with an in vitro model following the application of 
diclofenac  products : Flector¬Æ (diclofenac epolamine  1.3% patch ) 
or Pennsaid¬Æ (diclofenac sodium  2% topi[INVESTIGATOR_166461]).   
 
Description of Study 
Design:  The study will be an open -label , non-placebo controlled , 
crossover  study  (n=12  healthy  subjects)  over 10 weeks includes 
three study sessions and up to a 45 day screening period  with 
one week washout period between study sessions . 
The study contain s nine procedure days : 
Study Session 1  
‚Ä¢ Procedure Day 1:   Flector¬Æ patches ( 4 patches ) containing 
1.3% diclofenac  epolamine to be worn for 10 h.  Blood 
samples obtained on Procedure Day s 1, 2 and 3. 
 
Study Session 2  
‚Ä¢ Procedure Day 4:  Pennsaid¬Æ topi[INVESTIGATOR_166461] ( 2 g of 
solution applied to 200 cm2 area on each upper arm  for a 
total of 4 g ) containing diclofenac sodium to be worn for 6 h.  
Blood samples obtained on Procedure Day s 4, 5 and 6. 
 
Study Session 3  
‚Ä¢ Procedure Day 7:  Six applications of  Flector¬Æ 1.3% patch  
pi[INVESTIGATOR_507697]¬Æ topi[INVESTIGATOR_166461]  2%; 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
4 removal of patches  at 10 h  and solution  at 6 h, followed by 
[CONTACT_451514][INVESTIGATOR_58104] 10 h and 6 h, respectively  (Uptake  or 
Absorption ) 
‚Ä¢ Procedure Day 8:  Tape strippi[INVESTIGATOR_25577] 27 or 23 h [17 h after 
removal]  (Clearanc e) 
‚Ä¢ Procedure Day 9:   Tape strippi[INVESTIGATOR_25577] 51 or 47 h [41 h after 
removal] (Clearance)  
A)  Pharmacokinetics  
Each subject will be his/her own control  (pre-dose blood 
sample) and each subject will sign an institutional review board ‚Äì
approved consent form explaining the purpose, nature, risks, 
benefits, and duration of the study. The study will be conducted 
in accordance with good clinical practice guidelines and with the 
ethical  principles originating in the Declaration of Helsinki.  
The subject‚Äôs skin in the area of application will be relatively free 
of hair before patch  and topi[INVESTIGATOR_507698]. For each 
treatment , the patch /solution  will be applied to a previously 
unused application site. Blood samples (approximately 5 mL  (1 
tsp) each) will be drawn in BD vacutainer  tubes .  On Procedure 
Days 1, 2, 3, 4, 5  and 6, blood samples will be obtained as 
follows:  
‚Ä¢ Within 60  min pre -patch/solution  application and then up to 
[ADDRESS_655060] 
patch/solution  removal.   No blood samples will be obtained 
during  Procedure Days 7, 8 and 9. 
 B)  Residual Drug Analysis of Diclofenac Patches  
In conjunction with the above described study residual drug 
analysis will also be conducted for the previously worn Flector¬Æ 
patches  and patch pi[INVESTIGATOR_507699] 1 -3.    
‚Ä¢ Prior to administration to the subject as described in Part A, 
the patches  will be weighed and the weight recorded.  
‚Ä¢ The pouch, release liner and all items coming into contact 
[CONTACT_507721]  (gloves, forceps, etc.) to be applied in Part 
A will be retained for analysis.    
‚Ä¢ The used patches  will be retained for drug content anal ysis.  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
5 ‚Ä¢ Upon removal of the patches  after appropriate  wear time, the 
skin (at site of application) will be swabbed and the swab 
retained for drug content analysis.  
‚Ä¢ All items coming into contact [CONTACT_507722] a separate labeled 
sealable pouch for analytical retention and drug content  
analysis .   
C) Tape Strippi[INVESTIGATOR_007]  (TS) of diclofenac  patch and topi[INVESTIGATOR_166461]  
(Study Session 3)  
‚Ä¢ Diclofenac products ( 6 sites/product, 3 sites/arm/product) will 
be applied to each arm.  All of the patches will be removed 
at [ADDRESS_655061] of the solution sites at 6 h will be tape 
stripped (uptake  or absorption ), one-third of the patch sites 
at [ADDRESS_655062] of the solution sites at 23 h will be tape 
stripped (clearance) and remaining patch sites at 51 h and 
solution at 47 h will be tape stripped (clearance).     
‚Ä¢ Tape strips applied and removed after patch /solution  
removal are extracted to determine drug concentration in 
stratum corneum , which is the outer layer of the epi[INVESTIGATOR_49196].   
 
 
  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
6 1 KEY ROLES  
U01 Principal Investigator:  
  
[INVESTIGATOR_39432] L. Stinchcomb (contact), PhD, RPh  
[CONTACT_3348] of Pharmaceutical Sciences  
University of Maryland School of Pharmacy  
[ADDRESS_655063], Room PHN521  
Baltimore, MD [ZIP_CODE]  
Phone: 410 -706-2646  
Fax: 410 -706-0886  
Email: [EMAIL_768]   
  
  
Medically Accountable 
Investigator (s) 
 
 Jeffrey C Fink MD, MS  
[CONTACT_3348] of Medicine and Epi[INVESTIGATOR_623] (secondary)  
University of Maryland School of Medicine  
UMMC, Room NN3E03  
Baltimore, MD [ZIP_CODE]  
Phone: 410 -328-4822  
Fax: 410 -328-5685  
 E-mail: [EMAIL_769]  
 
 
Lee-Ann Wagner , MD  
University of Maryland School of Medicine  
 Department of Medicine  
 Pediatrics   
North Hospi[INVESTIGATOR_39433], MD [ZIP_CODE] [LOCATION_003]  
Phone:   [PHONE_702] or 410 -328-3158   
Email:  [EMAIL_6141]  
 
 
 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, [ADDRESS_655064]  is to investigate  the development of appropriate methods to 
determine  the in vitro/in vivo correlation (IVIVC) of drug absorption from dermal  
products, which has represented a longstanding challenge. The model drug for this 
study is diclofenac, which is available in two different formulations, patch and topi[INVESTIGATOR_507700], approved by [CONTACT_312173].  This healthy hum an subject study will 
provide the carefully designed protocols and data for direct comparison (IVIVC) with an 
in vitro human skin diffusion study model.  Generic drugs are approved based upon 
bioequivalence (BE) testing, and w ith respect to oral drug delivery, the accepted BE 
approach is relative ly straightforward and is principally based on matching blood level 
profiles. In some cases, in vitro dissolution tests can be done to help determine the 
bioequivalence of an oral dosage form.  For topi[INVESTIGATOR_507701], 
with the exception of corticosteroids  and a few other products , a comparative clinical 
endpoint study is often necessary for approval of a generic product or for replacement of 
an approved dermatological drug product with one that has major  changes. Comparative 
clinical trials are relatively insensitive, time -consuming and costly .  It is especially difficult  
to gain the adequate statistical power needed to evaluate bioequivalence in some 
dermatological conditions, and can require a large number (i.e., hundreds1,2) of subjects.  
This study supports FDA‚Äôs continuing effort to identify the most accurate, sensitive, 
reproducible and e fficient methods to evaluate topi[INVESTIGATOR_312168] .  
In 1998, the FDA issued draft guidance for the dermatopharmacokinetics ( DPK) method 
to assess the bioequivalence of topi[INVESTIGATOR_507702]3. The 
approach req uired quantification of the total amount of drug in the stratum corneum  
(SC) as a function of time, akin to the typi[INVESTIGATOR_507703] -time profiles of traditional PK 
studies using blood sampling. Tape -strippi[INVESTIGATOR_007], a technique that involves multiple 
applicat ions and removal of individual pi[INVESTIGATOR_507704] a formulation -treated area of the 
skin of a healthy human subject, is the biosampling method used in TS to remove layers 
of the SC in serial.  The draft guidance was withdrawn in 2002 following the inconsistent 
results of two studies4. The lack of agreement in the results prompted concern about 
both the reproducibility and the adequacy of this method to assess drugs whose target 
site is beyond the SC.  
Considerable subsequent effort was directed at identifi cation of problems/limitations of 
the original TS protocol and development of an improved procedure to generate 
reproducible data of much higher quality5,6.   
The end product of this research was a relatively straightforward method that examines 
only one uptake and one elimination time per fo rmulation. This allows replicate sites to 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
8 be studied, and higher statistical power to be achieved with fewer volunteers. No tapes 
are discarded, but tapes are combined and extracted in groups to achieve high 
concentrations for analysis. The total amount of  drug in the SC is measured for each 
site, and the ratios of these quantities for a  reference listed drug  (RLD) and test 
formulations can then be compared in the usual ‚Äú80:125‚Äù area under the curve 
bioequivalence fashion .  The method has been successively applied retrospectively to 
the comparison of retinoid gels and prospectively to the analysis of DPK data obtained 
for [ADDRESS_655065], repr esent suitable in vivo information for comparison and 
correlation with in vitro skin penetra tion. This study will evaluate  two commercially 
available products; Flector¬Æ (diclofenac  1.3% patch ) and Pennsaid¬Æ 2% diclofenac 
topi[INVESTIGATOR_507705].  One uptake/absorption TS time 
point sample will be obtained , and two clearance time points will be obtained .  Important 
systemic pharmacokinetic data in the form of blood drug levels will also be gathered 
during an identica l protocol of absorption and clearance phase, in order to be able to 
cross compare all three methods, in vivo systemic PK, in vivo TS, and in vitro 
permeation techniques for thorough IVIVC.  The diclofenac patch and topi[INVESTIGATOR_507706] . Upon completion of this in vivo study, skin 
and blood diclofenac levels obtained after application of each product will be coupled 
with in vitro data generated in our laboratory at UMSOP to develop IVIVC models. These 
models would help in predicting in vivo skin and blood diclofenac levels from in vitro 
studies.   The measurement of blood drug levels is the gold standard test for evaluation 
of phar macokinetic parameters  for systemically acting products .  The systemic blood 
levels measured in this study will allow us to evaluate  the TS and in vitro studies, as 
these latter two methods are currently not accepted as regulatory standard of practice.   
Some topi[INVESTIGATOR_507707], so in that 
case, future surrogate methods for clinical endpoint studies may be using TS or in vitro 
studies.   The diclofenac product has systemic absorption to allow us to validate the t wo 
non-standard techniques.  
 
2.2 Rationale  
The goal of this study is to help establish more efficient pathways for approval of topi[INVESTIGATOR_507708]. This study with Flector¬Æ 
(diclofenac epolamine 1.3 %) topi[INVESTIGATOR_507709]¬Æ (diclofenac sodium 2 %) topi[INVESTIGATOR_507710]. Th e systemic concentration  will be compared with the local 
bioavailability of diclofenac  in the skin using th e products, measured by [CONTACT_507723]. The same products  will also be 
studied (under a parallel but separate in vitro study protocol) using an in vitro permeation 
test (IVPT) model with excised human ski n which has demonstrated IVIVC in previous 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
9 studies. This research will help establish whether the IVPT model correlates with and is 
predictive of in vivo bioavailabil ity, and whether IVPT and/or  in vivo  TS can be utilized as 
part of a collective weight -of-evidence approach to support an approval pathway for 
topi[INVESTIGATOR_312163].  
 
The multi -dimensional design of the current study minimizes the human subject research 
that would otherwise be expanded by [CONTACT_507724] s local and systemic bioavailability, all of which can be now be directly compared in 
this study to support multiple, inter -relate d in vivo analyses relating to the bioavailability 
and bioequivalence.  These coordinated evaluations also collectively provid e the in vivo 
reference datasets that are needed to establish IVIVC for the IVPT model which may then 
be utilized to support a new pathway for approval of numerous topi[INVESTIGATOR_507711].  
Flector¬Æ patch and  Pennsaid¬Æ topi[INVESTIGATOR_507712]¬Æ 1.3% patch  Pennsaid¬Æ 2% topi[INVESTIGATOR_507713]  1,3-butylene glycol, 
dihydroxyaluminum 
aminoacetate, disodium 
edetate, D -sorbitol, 
fragrance (Dalin PH), 
gelatin, kaolin, 
methylparaben, 
polysorbate 80, povidone, 
propylene glycol, 
propylparaben, sodium 
carboxymethylcellulose, 
sodium polyacrylate, 
tartaric acid, titanium  
dioxide and purified water  dimethyl sulfoxide USP 
(DMSO, 45.5% w/w), 
ethanol, purified water, 
propylene glycol and 
hydroxypropyl cellulos e 
    
Formulation  patch  topi[INVESTIGATOR_507714]., Ltd  Horizon Pharma [LOCATION_003] Inc.  
  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
10 3 OBJECTIVES  
3.1 Study Objectives  
1)  G enerate human PK data for the purpose of establishing an IVIVC  model by 
[CONTACT_507725] :  Flector¬Æ 1.3% 
diclofenac epolamine  patches and Pennsaid¬Æ 2% diclofenac sodium topi[INVESTIGATOR_166461] . 
 
2)  Generate TS data for the purpose of establishing a fundamental IVIVC model by 
[CONTACT_507726] :  Flector¬Æ 1.3% diclofenac epolamine patches and Pennsaid¬Æ 2% 
diclofenac sodium topi[INVESTIGATOR_166461] . 
   
3.2 Study Outcome Measures  
For the TS study the main outcome measure is the ratio of clearance and uptake of 
diclofenac drug concentrations for each diclofenac formulation. For the PK study t he 
main outcome measure is the maximum serum  concentration (C max); time of maximum 
serum  concentration (T max) of diclofenac  and area under the curve (AUC) attained from 
Flector¬Æ 1.3% diclofenac epolamine patches and Pennsaid¬Æ 2% diclofenac sodium 
topi[INVESTIGATOR_166461] .  In addition, the residual drug content from worn Flecto r¬Æ patches will be 
determined in order to attempt to estimate total amount of absorbed diclofenac .     
  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
11 4   STUDY DESIGN  
This is designed as an open -label, non-placebo controlled , crossover  study. The 
products tested are already FDA approved; however, the products are used outside of 
the approved indications by [CONTACT_507727].  The products being tested are for 
research purposes only; this is not a treatment study.  The study is not blinded because 
PK and TS assessment i s not subject to participant and/or observer bias.  The study will 
consist of three  study sessions .  Each of the [ADDRESS_655066] a one week washout period between each study 
session.   
 
The studies are as follows : 
 
STUDY SESSION  1 (PK study)  
Procedure Day 1:  Four Flector¬Æ patches [140 cm2 each ; two patches/arm ] will be 
applied for 1 0 h and removed.  Blood  samples will be collected at specified times .   
Procedure Day 2 :  Blood samples will be collected at specified times .   
Procedure Day 3 :  Blood samples will be collected at specified times .  There will be at 
least a one week washout period before proceeding to the next study session.  
 
STUDY SESSION  2 (PK study)   
Procedure Day 4:  Pennsaid¬Æ topi[INVESTIGATOR_166461] [ 4 g of solution  over 400 cm2 area; 2 
g/200 cm2 on each upper arm ] will be applied to the skin for 6 h and removed.  Blood 
samples will be collected at specified times .   
Procedure Day 5 :  Blood samples will be collected at specified times .   
Procedure Day 6 :  Blood samples will be collected at specified times .  There will be at 
least a one week washout period before proceeding to the next study session.  
 
STUDY SESSION  3 (TS study)   
Procedure Day 7:  Six sites ( 3 sites/arm/product) will be designated on the volar 
forearms for each diclofenac product and 1 site for a negative control  (volar skin area 
where  no drug is applied) . Flector¬Æ 1.3% patches [8.25 cm2 each ] and Pennsaid¬Æ 2% 
topi[INVESTIGATOR_166461] [ 82.5 mg/ 8.25 cm2 each ] will be applied.   At [ADDRESS_655067]  will be tape stripped at the designated 
uptake  (absorption) time ( [ADDRESS_655068] application).     
Procedure Day 8:  An additional  two sites for each product  will be tape stripped at the 
designated clearance period ( [ADDRESS_655069] application ; [ADDRESS_655070] removal ). 
Procedure Day 9 :  The remaining two sites for each product will be tape stripped at the 
designat ed clearance period ([ADDRESS_655071] application; [ADDRESS_655072] removal).  
 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
12 5 STUDY ENROLLMENT AND WITHDRAWAL  
Only healthy adult volunteers who meet the inclusion/exclusion criteria will be eligible for 
enrollment into this study.  Twelve subjects will be recruited as well as at least another 
five alternates  who could replace subjects who drop out from the study for any 
unforeseen reason.  The  study population selected for this study includes healthy adult 
men and women without other comorbidities ages [ADDRESS_655073] 40% participants of each gender. There are no specific 
ethnicity/race categor y recruitment targets , although such information  will be recorded by 
[CONTACT_41314].  
5.[ADDRESS_655074] Inclusion Criteria  
Subjec ts are eligible for this study if they fulfill the inclusion criteria specified below:  
1. Men or non -pregnant , women who are of any ethnic background between the 
age of [ADDRESS_655075] be non -smokers (must have refrained from the use of nicotine -
containing substances, including tobacco products (e.g., cigarettes, cigars, 
chewing tobacco, snuff , gum, patches  or electronic cigarettes) over the previous 
2 months and are not cu rrently using tobacco products.  
3. Provide written informed consent before initiation of any of the study procedures.  
4. Agree not to participate in another clinical trial/study during the study period  or to 
participate in an investigational drug study for at le ast [ADDRESS_655076] study 
session .   
5. Able to adhere to the study protocol schedule and study restrictions.    
6. Able to participate in all study sessions.  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, [ADDRESS_655077] 2 4 cm (9.45 inches)  in length or of sufficient 
size that c an accommodate the products  to be tested in a study area that begins 
at least 5 cm  (1.97 inches)  above the wrist and ends a minimum of 0.5 cm  (0.197 
inches)  below the antecubital fossa  (i.e., the bend in the arm at the elbow ). 
8. Subjects have upper arms large enough to allow for the placement of two 140 
cm2 [21.7 in2] patches  (distance from acromion process of the scapula to 
olecranon process should be a minimum of 35 cm [13.8 inches]; ci rcumference of 
upper arm s should be a minimum of 28 cm [11. 02 inches]  and 200 cm2 [31 in2] 
area for application of solution . 
9. Subjects deemed to be healthy as judged by [CONTACT_312175] ( MAI) and determined by [CONTACT_9870], physical examination and 
medication history.  
10. Negative urine drug screening test  (cannabinoids, amphetamine s, barbiturate s, 
benzodiazepi[INVESTIGATOR_050], cocaine, methadone, opi[INVESTIGATOR_2573] s, PCP ). 
11. Have normal screening laboratories for white b lood cells ( WBC ), hemoglobin 
(Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogent 
(BUN ), creatinine, alanine transaminase ( ALT) and aspartate aminotransferase 
(AST). 
12. Have normal screening laboratories for urine protein and urine glucose.  
13. Female subjects must be of non -childbearing potential (as defined as surgically 
sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more 
than 1 year), or if of childbearing potential must be non -pregnant at the time of 
enrollment  and on the morning of each study day, and must agree to use 
hormonal or barrier birth control such as implants, injectables, combined oral 
contraceptives, some intrauterine devices (IUDs), sexual abstinence, or a 
vasectomized partner.  
14. Agrees not to donat e blood to a blood bank throughout participation in the study 
and at least [ADDRESS_655078] a normal ECG; must not have the following to be acceptable: pathologic Q 
wave abnormalities, significant ST ‚ÄìT wave changes, left ventricu lar hypertrophy, 
right bundle branch block, left bundle branch block. (sinus rhythm is between 55 ‚Äì
100 beats per minute).  
16. Have normal vital signs ( see Appendix C ) 
‚Ä¢ Temperature 35 -37.9¬∞C (95 -100.3¬∞F)  
‚Ä¢ Systolic blood pressure 90 -165 mmHg  
‚Ä¢ Diastolic blood pressure 60 -100 mmHg  
‚Ä¢ Heart rate 55 -100 beats per minute  
‚Ä¢ Respi[INVESTIGATOR_1487] 12 -20 breaths per minute  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, [ADDRESS_655079] Exclusion Criteria  
Subjects will be excluded for any of the following conditions/reasons:  
1. Women who are pregnant, lactating, breast feeding or have a positive serum 
pregnancy test at enrollment or positive urine pregnancy test on the morning of 
the first day of each study session.  
2. Smokers (current use or use over the previous 2 months of nicotine -containing 
substances, including tobacco products (e.g., cigarettes, cigars, chewing 
tobacco, snuff, gum, patch or electronic cigarettes).  
3. Participation in any ongoing investigational drug trial /study  or clinical drug 
trial/study.  
4. Histo ry as either reported by [CONTACT_507728] (MAI) of infectious disease or skin infection or of chronic skin 
disease (e.g., psoriasis, atopic dermatitis).  
5. History of diabetes.  
6. History of significant skin cancer s (e.g., melanoma, squamous cell carcinoma), 
except basal cell carcinomas that were superficial and did not involve the 
investigative site s. 
7. Body Mass Index (BMI) ‚â•30 kg/m2. 
8. History of chronic obstructive pulmonary disease or cor pulmonale, or 
substantially decreased respi[INVESTIGATOR_2607], hypoxia, hypercapnia or pre -existing 
respi[INVESTIGATOR_2341].  
9. Active positive Hepatitis B, C and /or HIV serologies  (see Appendix B ). 
10. Positive urine drug screening test.  
11. Use of any prescription medication during the period 0 to 30 days or over -the-
counter medication  e.g. antihistamines, topi[INVESTIGATOR_507715] 
0-5 days before entry to the study (vitamin s, herbal supplements and birth control 
medications not included) . 
12. Currently taking daily oral nonsteroidal anti -inflammatory drug [NSAIDs] (aspi[INVESTIGATOR_248], 
ibuprofen, naproxen, etc‚Ä¶).  
13. Currently taking daily anticoagulants or within the past month prior to entry into 
the study (warfarin, heparin, rivaroxaban, dabigatran, etc‚Ä¶)  ACE-inhibitors, 
cyclosporine, diuretics, lithium or methotrexate.  
14. Donation or loss of greater than one pi[INVESTIGATOR_39434] 60 days of entry to the 
study. 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
15 15. Any prior adverse reaction or hypersensitivity to diclofenac,  aspi[INVESTIGATOR_248] , ibuprofen, 
naproxen  or other nonsteroidal anti -inflammatory drug (NSAID) , other inactive 
ingredients  in the patch  or topi[INVESTIGATOR_507716].  
16. Received an experimental agent (vaccine, drug, biologic, device, blood product 
or medication) within 1 month before enrollment in this study or expects to 
receive an experimental agent during the study.  
17. Eat or d rink anything containing alcohol within 24 hours prior to dose 
administration.  
18. Any condition that would, in the opi[INVESTIGATOR_39435] 
(MAI), place the subject at an unacceptable risk of injury or render the subjec t 
unable to meet the requirements of the protocol.  
19. Subject has an obvious difference in skin color between arms or the presence of 
a skin condition, excessive hair at the application site ( upper arm s/volar 
forearm s), sunburn, raised moles and scars, open sores at application site ( upper 
arms/volar forearm s), scar tissue, tattoo, or coloration that would interfere with 
placement of diclofenac products , skin assessment, or reactions to diclofenac . 
20. History of asthma or urticaria , hypertension, myocardial  infarction, thrombotic 
events, stroke, congestive heart failure, impaired renal function  or liver disease . 
21. History of gastrointestinal bleeding or peptic ulcer disease.  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, [ADDRESS_655080] Description  
6.1.1  Flector¬Æ (diclofenac  epolamine  1.3%) patch  [140 cm2] 
Flector¬Æ is a prescription diclofenac -containing patch  that releases diclofenac  through 
the skin into the body.  The patch  releases diclofenac  over a 12  h period , the 
recommended duration  of patch  application. The patch is for the topi[INVESTIGATOR_2855] t reatment of 
acute pain due to minor strains, sprains and contusions.  
6.1.2  Pennsaid¬Æ (diclofenac  sodium 2 %) topi[INVESTIGATOR_507717]¬Æ 2% topi[INVESTIGATOR_507718] a prescription diclofenac -containing solution  that 
releases diclofenac  through the skin into the body.  The solution  releases diclofenac  
over a 12  h period . The solution  is a nonsteroidal anti -inflammatory drug (NSAID)  
indicated for the treatment of the pain from osteoarthritis of the knee(s).   
6.2 Formulation, Packaging, and L abeling  
6.2.1  Flector¬Æ (1.3% diclofenac  epolamine ) patch  
Active ingredient (in each patch): diclofenac  epolamine , 180 mg (13 mg per gram adhesive)  
in an aqueous base .  In addition to the active ingredient ( diclofenac  epolamine ), the 
following inactive ingredient s are present in the patch : dihydroxyaluminum aminoacetate, 
disodium edetate, D-sorbitol, fragrance (Dalin PH), gelatin, kaolin, methylparaben, 
polysorbate 80, povidone, propylene glycol, propylparaben, sodium carboxymethylcellulose, 
sodium polyacrylate, tartaric acid, titanium dioxide and purified  water . This patch  is 
manufactured by  [CONTACT_507729]., Ltd.  This product should be stored a t room 
temperature . 
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
17  
6.2.2  Pennsaid¬Æ 2% diclofenac  sodium  topi[INVESTIGATOR_507719]  1 g of solution  (20 mg  diclofenac sodium  per gram 
solution ).  In addition to the active ingredient ( diclofenac sodium ), the following inactive 
ingredients are present in the solution :  dimethyl sulfoxide USP (DMSO, 45.5% w/w), 
ethanol, purified water, propylene glycol and hydroxypropyl cellulose.  This solution  is 
manufactured by  [CONTACT_507730].  This product should be stored a t room 
temperature . 
 

PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, [ADDRESS_655081] the null 
hypothesis (H 0) that the mean clearance/uptake diclofenac  amount ratio, and the PK 
parameters (C max and AUC) between these products are different (i.e., outside the 80 ‚Äì
125% range).  
7.[ADDRESS_655082]. Blood samples (approximately 5 mL (1 tsp)) will be collected during Study 
Session [ADDRESS_655083] -patch application. Blood samples (approximately 5 mL (1 
tsp)) will be collected during Study Session [ADDRESS_655084] -solution application.   After the PK 
study , TS study  will be conducted at  10 h [patches] and 6 h [solution]  (skin drug 
uptake /absorption ), 27 h [patches] and 23 h [solution] (skin drug clearance), and 51 h 
[patches] and  47 h [solution]  (skin drug clearance)  post product  application.  Non 
compartmental  analyses (NCA) will be conducted to estimate the  PK parameters such 
as: maximum serum  concentration (C max); apparent elimination rate constant (k); 
apparent half -life (t 1/2), calculated as 0.693/k; AUC 0-last of the serum  concentration ‚Äìtime 
determined by [CONTACT_507731]; and AUC value extrapolated to infinity 
(AUC inf), calculated as the sum of AUC 0-last and the area extrapolated to infinity: AUC inf = 
AUC 0-last + C last/k where C last would be the last quantifiable concentration. All NCA 
analyses will be conduc ted using Phoenix¬Æ WinNonlin¬Æ 6.4 (Pharsight, a Certara 
Company, CA).  
7.3 Final Analysis Plan  
An objective of this study is to determine PK parameters (C max, AUC and ratio of SC 
drug concentration during uptake and clearance) of diclofenac  in healthy adults and TS 
data after using Flector¬Æ (diclofenac  epolamine 1.3 % patch ) and Pennsaid¬Æ (2% 
diclofenac  sodium  topi[INVESTIGATOR_166461] ) for the purpose of IVIVC  by [CONTACT_507732] .  
PK and TS of Diclofenac Dermal Products  Version 11.0; June 7, 2019  
 ________________________________ ________________________________ ____________________________   
 ________________________________ ________________________________ ____________________________   
19 Analysis of variance (ANOVA) followed by [CONTACT_447] -hoc Bonferroni test will be used for 
comparing the differences in the means of the PK parameters and significant differences 
will be declared at p<0.0 5. The statistical comparisons will be conducted as follow:  
 
If diclofenac  PK concentrations are found to be non -normally distributed, then we will 
examine Box -Cox transformations (e.g., log, square -root, etc.) that can achieve 
normality. If no transformat ion can achieve normality, then will use permutation tests to 
compute empi[INVESTIGATOR_10477] p-values, and will use the bootstrap to compute standard errors and 
confidence intervals that account for within -person correlation.  
  
IVIVC will be conducted comparing PK parameters and profiles to predicted PK 
parameters and profiles using IVPT and  in vitro  TS results.  Multiple methods will be 
implemented to develop an IVIVC.  The first method is to compare the steady state 
concentrations.  The predicted stea dy state concentration using IVPT data will employ 
the following formula:  
ùê∂ùë†ùë†=ùêΩùë†ùë† ‚àóùê¥
ùê∂ùêø 
 
The second method will compare the PK profiles of the clinical and IVPT study by 
[CONTACT_507733].   The third method will be to determine and compare resid ual 
patch analysis between in vitro  and in vivo .    
 
In terms of developi[INVESTIGATOR_507720] a comparison will be made between in 
vitro and in vivo  uptake  (absorption)  and clearance diclofenac  amounts.  The second 
method is to compare the clearanc e to uptake diclofenac  amount ratio between  in vitro 
and in vivo . 
 